BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 8872329)

  • 1. FISH detection of HER-2/neu oncogene amplification in early onset breast cancer.
    Xing WR; Gilchrist KW; Harris CP; Samson W; Meisner LF
    Breast Cancer Res Treat; 1996; 39(2):203-12. PubMed ID: 8872329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.
    Press MF; Bernstein L; Thomas PA; Meisner LF; Zhou JY; Ma Y; Hung G; Robinson RA; Harris C; El-Naggar A; Slamon DJ; Phillips RN; Ross JS; Wolman SR; Flom KJ
    J Clin Oncol; 1997 Aug; 15(8):2894-904. PubMed ID: 9256133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of HER-2/neu overexpression and/or gene amplification in breast carcinomas: should in situ hybridization be the method of choice?
    Sauer T; Wiedswang G; Boudjema G; Christensen H; Karesen R
    APMIS; 2003 Mar; 111(3):444-50. PubMed ID: 12752225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization.
    Persons DL; Borelli KA; Hsu PH
    Mod Pathol; 1997 Jul; 10(7):720-7. PubMed ID: 9237184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization.
    Pauletti G; Godolphin W; Press MF; Slamon DJ
    Oncogene; 1996 Jul; 13(1):63-72. PubMed ID: 8700555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluorescence in situ hybridization (FISH) for detection of HER-2/neu amplification in breast cancer: a multicenter portability study.
    Persons DL; Bui MM; Lowery MC; Mark HF; Yung JF; Birkmeier JM; Wong EY; Yang SJ; Masood S
    Ann Clin Lab Sci; 2000 Jan; 30(1):41-8. PubMed ID: 10678582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry.
    Pauletti G; Dandekar S; Rong H; Ramos L; Peng H; Seshadri R; Slamon DJ
    J Clin Oncol; 2000 Nov; 18(21):3651-64. PubMed ID: 11054438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER-2 status in breast cancer: correlation of gene amplification by FISH with immunohistochemistry expression using advanced cellular imaging system.
    Ciampa A; Xu B; Ayata G; Baiyee D; Wallace J; Wertheimer M; Edmiston K; Khan A
    Appl Immunohistochem Mol Morphol; 2006 Jun; 14(2):132-7. PubMed ID: 16785779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Her-2/neu Oncogene Amplification by Fluorescence In Situ Hybridization and Protein Overexpression on Immunohistochemistry in Breast Cancer.
    Lateef F; Jamal S; Nasir S
    J Coll Physicians Surg Pak; 2018 Aug; 28(8):581-585. PubMed ID: 30060783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer.
    Paterson MC; Dietrich KD; Danyluk J; Paterson AH; Lees AW; Jamil N; Hanson J; Jenkins H; Krause BE; McBlain WA
    Cancer Res; 1991 Jan; 51(2):556-67. PubMed ID: 1670762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of p34cdc2 cyclin-dependent kinase and MIB1 overexpression, and HER-2/neu gene amplification detected by fluorescence in situ hybridization in breast cancer.
    Depowski PL; Brien TP; Sheehan CE; Stylos S; Johnson RL; Ross JS
    Am J Clin Pathol; 1999 Oct; 112(4):459-69. PubMed ID: 10510669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization.
    Hammock L; Lewis M; Phillips C; Cohen C
    Hum Pathol; 2003 Oct; 34(10):1043-7. PubMed ID: 14608539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material.
    Xu R; Perle MA; Inghirami G; Chan W; Delgado Y; Feiner H
    Mod Pathol; 2002 Feb; 15(2):116-24. PubMed ID: 11850540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization.
    Ross JS; Sheehan C; Hayner-Buchan AM; Ambros RA; Kallakury BV; Kaufman R; Fisher HA; Muraca PJ
    Hum Pathol; 1997 Jul; 28(7):827-33. PubMed ID: 9224752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of HER-2/neu (c-erb B-2) DNA amplification in primary breast carcinoma. Interobserver reproducibility and correlation with immunohistochemical HER-2 overexpression.
    Tsuda H; Akiyama F; Terasaki H; Hasegawa T; Kurosumi M; Shimadzu M; Yamamori S; Sakamoto G
    Cancer; 2001 Dec; 92(12):2965-74. PubMed ID: 11753973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER-2/neu gene amplification by fluorescence in situ hybridization allows risk-group assessment in node-negative breast cancer.
    Harbeck N; Ross JS; Yurdseven S; Dettmar P; Pölcher M; Kuhn W; Ulm K; Graeff H; Schmitt M
    Int J Oncol; 1999 Apr; 14(4):663-71. PubMed ID: 10087312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER-2/neu gene amplification in stages I-IV breast cancer detected by fluorescent in situ hybridization.
    Mark HF; Aswad B; Bassily N; Taylor W; Brown S; Sun CL; Samy M; Zolnierz K; Wong E; Bland KI; Hsu PH
    Genet Med; 1999; 1(3):98-103. PubMed ID: 11336460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of HER-2/neu, c-myc amplification and p53 inactivation by FISH in Egyptian patients with breast cancer.
    Ismail MF; Aly MS; Khaled HM; Mohamed HM
    Ger Med Sci; 2009 May; 7():Doc03. PubMed ID: 19675743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluorescence in situ hybridization and immunohistochemical assays for HER-2/neu status determination: application to node-negative breast cancer.
    Onody P; Bertrand F; Muzeau F; Bièche I; Lidereau R
    Arch Pathol Lab Med; 2001 Jun; 125(6):746-50. PubMed ID: 11371225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER-2/neu amplification detected by fluorescence in situ hybridization in fine needle aspirates from primary breast cancer.
    Bozzetti C; Nizzoli R; Guazzi A; Flora M; Bassano C; Crafa P; Naldi N; Cascinu S
    Ann Oncol; 2002 Sep; 13(9):1398-403. PubMed ID: 12196365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.